{"id":2037,"date":"2024-04-12T13:34:54","date_gmt":"2024-04-12T13:34:54","guid":{"rendered":"https:\/\/stoxpo.com\/?p=2037"},"modified":"2024-04-12T13:34:56","modified_gmt":"2024-04-12T13:34:56","slug":"paxmedica-completes-milestone-for-suramin-iv-formulation-nears-fda-submission","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/04\/12\/paxmedica-completes-milestone-for-suramin-iv-formulation-nears-fda-submission\/","title":{"rendered":"PaxMedica Completes Milestone for Suramin IV Formulation, Nears FDA Submission"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Biopharmaceutical Company Advances Potential Treatment for Fatal Tropical Disease and Autism Spectrum Disorder<\/h4>\n\n\n\n<p>PaxMedica (PXMD) has achieved a significant milestone with the completion of its three pivotal registration\/validation batches of PAX-101, an IV formulation of suramin. This achievement paves the way for a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in Q4 2024, marking a crucial step towards the potential commercial availability of the first suramin form for the treatment of Stage 1 Human African Trypanosomiasis (HAT), a fatal tropical disease.<\/p>\n\n\n\n<p>With PAX-101 already established as the standard treatment outside the United States for HAT, PaxMedica&#8217;s progress signifies a significant breakthrough in addressing neglected tropical diseases. Moreover, successful FDA approval could qualify the company for a Tropical Disease Priority Review Voucher (PRV), incentivizing further research and development in this critical area.<\/p>\n\n\n\n<p>Howard Weisman, Chairman and CEO of PaxMedica, emphasized the company&#8217;s commitment to advancing treatments not only for HAT but also for Autism Spectrum Disorder. By ensuring a sustainable global supply chain for PAX-101, PaxMedica aims to expand its clinical investigations to explore the potential of suramin in treating the core symptoms of Autism Spectrum Disorder. This milestone underscores PaxMedica&#8217;s dedication to addressing some of the most challenging neurological conditions with innovative treatments.<\/p>\n\n\n\n<p>Read original press release:<a href=\"https:\/\/finance.yahoo.com\/news\/paxmedica-achieves-key-milestone-development-203000354.html\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">here<\/mark><\/a><\/p>\n\n\n\n<p>You might like this article: <a href=\"https:\/\/stoxpo.com\/index.php\/2024\/04\/12\/gold-hits-record-high-amid-escalating-middle-east-tensions\/\" target=\"_blank\" rel=\"noreferrer noopener\">Gold Hits Record High Amid Escalating Middle East Tensions<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biopharmaceutical Company Advances Potential Treatment for Fatal Tropical Disease and Autism Spectrum Disorder PaxMedica (PXMD) has achieved a significant milestone with the completion of its three pivotal registration\/validation batches of PAX-101, an IV formulation of suramin. This achievement paves the way for a New Drug Application (NDA) submission to the U.S. Food and Drug Administration [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1422,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"format":"standard"},"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[]},"categories":[358,309],"tags":[],"coauthors":[453],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2037"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=2037"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2037\/revisions"}],"predecessor-version":[{"id":2038,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2037\/revisions\/2038"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1422"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=2037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=2037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=2037"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=2037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}